


FASN-IN-4

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-12648 | | |
| CAS No.: | 1375105-96-6 | | |
| Molecular Formula: | C ₂₆ H ₂₇ N ₃ O ₄ S | | |
| Molecular Weight: | 477.58 | | |
| Target: | Fatty Acid Synthase (FASN); SARS-CoV | | |
| Pathway: | Metabolic Enzyme/Protease; Anti-infection | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC ₅₀ of 10 nM (WO2012064642A1, compound 29) ^[1] . FASN-IN-4 also inhibits SARS-CoV-2 with an EC ₅₀ of 18.6 nM ^[2] . |
| IC₅₀ & Target | IC ₅₀ : 10 nM (FASN) ^[1] EC ₅₀ : 18.6 nM (SARS-CoV-2) ^[2] |
| In Vitro | The FASN inhibitor, FASN-IN-4 inhibits SARS-CoV-2 replication, and has the potential for COVID-19 research ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

CUSTOMER VALIDATION

- Nat Metab. 2021 Sep 27;1-10.
- Sci China Life Sci. 2021 May 27;1-21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Nicholas D. Adams, et al. Fatty acid synthase inhibitors. WO2012064642A1.

[2]. Junjun Chu, et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat Metab. 2021 Nov;3(11):1466-1475.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA